BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Merck  Sharp  and  Dohme  Limited  submitted  on  6  December  2000  an  application  for 
Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) 
for  Invanz  (ertapenem),  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  25 
September  2000,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to  Council 
Regulation No (EEC) 2309/93 of 22 July 1993 as amended. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr F. Rotblat 
Co-Rapporteur:  Prof Silva Lima 
Scientific Advice: 
The applicant did not seek scientific advice from the CPMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 26 December 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  6  March 
2001.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
19 March 2001. 
During  the  meeting  on  24-26  April  2001,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 26 April 2001. 
The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  11 
July 2001. 
The Rapporteur circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CPMP members on 17 September 2001. 
During the meeting on 16-18 October 2001, the CPMP agreed on a List of Outstanding Issues to 
be  addressed  by  the  applicant  in  writing  and  during  an  oral  explanation.  The  final  List  of 
Outstanding Issues was sent to the applicant on 18 October 2001. 
The applicant provided responses to the List of Outstanding Issues on 22 November 2001. 
The  Rapporteur  circulated  the  Assessment  Report  on  the  applicant’s  responses  to  the 
pharmaceutical outstanding issues to all CPMP members on 7 December 2001. 
During the CPMP meeting on 11-13 December 2001, outstanding issues were addressed by the 
applicant during an oral explanation before the CPMP. 
The  applicant  provided  an  undertaking  letter  of  the  follow-up  measures  to  be  fulfilled  post-
authorisation on 17 January 2002. 
During the meeting on 15-17 January 2002 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  by  majority  for 
granting a Marketing Authorisation to Invanz on 17 January 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which issued the corresponding Decision on 18 April 2002. 
1/1 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
